Current understanding of endothelial function and the role of endothelial dysfunction in cardiovascular diseases provides the rational basis for the development of a novel field in pharmacology–pharmacology of endothelium. Although it focuses on the treatment of vascular endothelium and vascular wall, it is therapeutically applicable to a vast range of diseases, such as atherosclerosis, and vascular complications thereof (e.g. myocardial infarction), heart failure postoperative vascular complications, pulmonary hypertension, microangiopathies of neurodegenerative diseases, and many others. In fact, searching for effective endothelium–targeted therapeutics may also bear new therapeutic opportunities for prevention and treatment of diseases such as liver steatosis, chronic liver inflammation, diabetes and cancer metastasis, that still represent unmet medical needs.
It is thus clear today, that the studies on the pharmacotherapeutic mechanisms of endothelium and vascular wall leading to the development of novel endothelium–targeted therapeutics opens new therapeutic possibilities for the treatment of many diseases. On the other hand, evaluation of the vascular safety of drugs should constitute an important criterion in preclinical drug development.
Endothelial profiling–the specialized and comprehensive evaluation of the effects of chemical compounds on endothelium–is offered by JCET, a newly established academic research centre of the Jagiellonian University, together with consortium of partners in Poland. This offer of comprehensive research service involves also variety of disease models to study efficacy, as well as to evaluate pharmacokinetic profile of compounds.
More information about Endothelial Profling